Developer docs
API playgroundTry for free, no card

Search company profiles

GeneFirst

Full company profile

uuid00045ow

Namestring
GeneFirst
Legal namestring
GeneFirst Limited
Websiteurl
genefirst.com
Company typeenum
Private
Founded yearint
2011
Descriptiontext

GeneFirst Limited is a privately-held molecular diagnostics company founded in 2011 and headquartered at Abingdon Science Park, Oxfordshire, UK. It develops and commercialises proprietary NGS library preparation and qPCR technologies for infectious disease, cancer diagnostics, and personalised medicine, serving healthcare laboratories, researchers, and pharmaceutical/drug companies. Its technology platform is anchored by ATOM-Seq (Adaptor Template Oligo Mediated Sequencing), a patented ligation-free NGS library preparation method that incorporates Unique Molecular Identifiers directly onto sample molecules, complemented by MPA (Multiplex Probe Amplification), MMD-PCR (Multiplex Mutation Detection PCR), and PCDR (Polymerase Chain Displacement Reaction) chemistries. The commercial product portfolio comprises the XCeloSeq NGS kit family (targeted cfDNA, FFPE DNA/RNA, fusion detection, methylation, and custom panels), the CE-IVD marked Papilloplex HR-HPV DNA and mRNA kits for cervical cancer screening, CE-IVD marked Upper and Lower Respiratory Panels, and qPCR mutation detection kits (JAK2 V617F, ABL T315I).

The company generates revenue primarily through one-time sales of its diagnostic kits and NGS reagents, supplemented by a technology licensing channel for MPA and MMD. Distribution is quote-based, executed through direct sales in the UK and a network of regional distributors covering 20+ countries across the Americas, Asia-Pacific, Europe, and the Middle East, with manufacturing under ISO:13485 certification. To date the company has been funded almost entirely through competitive non-dilutive grants — two Innovate UK awards (2017), a €2.9M Horizon 2020 grant (2018), and a £1.4M NIHR grant with the University of Leeds (2021) — rather than venture capital, and has no disclosed PE, VC, or parent company ownership. Recent strategic activity includes Thai FDA approval for the Papilloplex HR-HPV kits and the launch of second-generation XCeloSeq cfDNA kits, both in June 2026, alongside active academic and consortium partnerships in HPV, respiratory, and oncology applications.

Short descriptiontext

GeneFirst is a UK-based molecular diagnostics company that develops proprietary NGS (ATOM-Seq) and qPCR (MPA, MMD-PCR) kits for oncology, infectious disease, and personalised medicine, serving healthcare laboratories, researchers, and pharmaceutical companies through direct UK sales and a global distributor network.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersAbingdon, United Kingdom
HQ citystring
Abingdon
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
molecular diagnostics kits, NGS library preparation, cancer mutation detection, HPV genotyping assays, respiratory pathogen PCR
Industry3 codes
PRIMARYHLAHAAAD
Molecular Diagnostics (PCR/NAAT/NGS-based IVD)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAGAIAF
Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays)
SECONDARYHLAAALAL
Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays)
NAICS code1 code
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Molecular Diagnostics
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1NGS Library Preparation Kits
TypeOne Time License
Description

Sale of XCeloSeq product line including targeted cfDNA kits, FFPE DNA/RNA kits, fusion detection kits, and total cfDNA capture kits for next-generation sequencing applications.

genefirst.com
2qPCR Diagnostic Kits
TypeOne Time License
Description

Sale of HPV screening assays (Papilloplex HR-HPV DNA and mRNA kits), respiratory infection panels (Upper and Lower Respiratory Panels), and mutation detection kits (JAK2, ABL).

genefirst.com
3Technology Licensing
TypeLicensing Royalties
Description

Licensing opportunities available for MPA and MMD technologies to other companies.

genefirst.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Supply Chain, Technology or R&D, Personnel, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

GeneFirst develops and manufactures proprietary molecular diagnostic kits and reagents based on its patented ATOM-Seq NGS capture chemistry and MPA/MMD/PCDR qPCR technologies. The company's commercial product range spans CE-IVD marked HPV and respiratory infection assays, XCeloSeq NGS kits for liquid biopsy and FFPE tissue analysis across multiple cancer types, and qPCR mutation detection kits targeting oncology biomarkers. These products are sold to researchers, clinical laboratories, and pharmaceutical companies for cancer diagnostics, infectious disease detection, and personalised medicine applications.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • ATOM-Seq captures up to 179% more cfDNA molecules compared to ligation-based capture chemistry
+3 more records
Product overview1 text field

GeneFirst is a molecular diagnostics company offering a portfolio of proprietary NGS library preparation and qPCR technologies focused on oncology, infectious diseases, and personalised medicine. The core technology platform is ATOM-Seq (Adaptor Template Oligo Mediated Sequencing), a patented ligation-free NGS library preparation method that incorporates Unique Molecular Identifiers (UMIs) directly onto sample molecules, which underpins the XCeloSeq product line for targeted and whole-sample cfDNA/FFPE DNA/FFPE RNA analysis. The qPCR portfolio includes MPA (Multiplex Probe Amplification) technology enabling high-throughput multiplex detection and MMD-PCR (Multiplex Mutation Detection PCR) for cancer mutation detection. Product portfolio spans: (1) NGS kits including targeted cfDNA kits for liquid biopsy mutation detection (Colon, Lung, Breast Cancer, Pan Cancer), FFPE DNA/RNA kits for fusion detection across multiple cancer types, and total cfDNA capture kits including methylation analysis; (2) CE-IVD marked diagnostic kits including Papilloplex HR-HPV DNA and mRNA assays for cervical cancer screening, and Upper/Lower Respiratory Panels for infectious disease detection; (3) qPCR mutation detection kits for JAK2 and ABL markers. All products are supported by ISO:13485 certified manufacturing at the Oxfordshire facility.

Product and service23 records
1Papilloplex HR-HPV DNA Kit (CE-IVD)
CategoryInfectious disease / HPV diagnostic kit
Description

CE-IVD marked qPCR assay based on MPA technology for simultaneous detection and differentiation of 14 high-risk HPV genotypes (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68) targeting the E6/E7 region with 100% clinical sensitivity, intended for cervical cancer screening laboratories.

2Papilloplex HR-HPV mRNA Kit (CE-IVD)
CategoryInfectious disease / HPV diagnostic kit
Description

CE-IVD marked qPCR assay that detects E6/E7 mRNA expression from high-risk HPV genotypes to identify cervical cancer risk in HPV-positive individuals, complementing the Papilloplex HR-HPV DNA Kit.

3Upper Respiratory Panel (CE-IVD)
CategoryRespiratory infection diagnostic kit
Description

CE-IVD marked multiplex PCR test detecting 11 pathogens in upper respiratory tract specimens including Adenovirus, Bocavirus, HCoV strains, hPIV1-4, Influenza A/B, Metapneumovirus, Mycoplasma pneumoniae, RSV, Rhinovirus, and SARS-CoV-2 variants.

4Lower Respiratory Panel (CE-IVD)
CategoryRespiratory infection diagnostic kit
Description

CE-IVD marked multiplex PCR test detecting 9 pathogens associated with community-acquired pneumonia including Bordetella pertussis, Coxiella burnetii, Haemophilus influenzae, Legionella pneumophila, Moraxella catarrhalis, Pneumocystis jirovecii, Staphylococcus aureus, and Streptococcus pneumoniae.

5XCeloSeq Colon Cancer cfDNA Kit V2
CategoryNGS library preparation kit
Description

Targeted cfDNA enrichment kit using ATOM-Seq v2 capture chemistry to detect mutations across hotspot regions of 22 colon cancer genes and 5 DPYD pharmacogenetics SNPs from liquid biopsy samples (SEQ031).

6XCeloSeq Lung Cancer cfDNA Kit V2
CategoryNGS library preparation kit
Description

Targeted cfDNA enrichment kit using ATOM-Seq v2 capture chemistry to detect mutations across 17 genes frequently mutated in lung cancer from liquid biopsy samples (SEQ032).

7XCeloSeq Breast Cancer cfDNA Kit V2
CategoryNGS library preparation kit
Description

Targeted cfDNA enrichment kit using ATOM-Seq v2 capture chemistry to detect mutations across 12 genes frequently mutated in breast cancer from liquid biopsy samples (SEQ033).

8XCeloSeq Pan Cancer cfDNA Kit V2
CategoryNGS library preparation kit
Description

Targeted cfDNA enrichment kit using ATOM-Seq v2 capture chemistry for pan-cancer liquid biopsy mutation profiling across multiple tumour types.

9XCeloSeq Fusion Research Kit
CategoryNGS library preparation kit
Description

NGS library preparation kit (SEQ007) using ATOM-Seq technology to capture and enrich gene fusions from 74 genes involved in chromosomal rearrangements in cancer, detecting both known and unknown fusion events from FFPE RNA samples.

10XCeloSeq Precision Colon Cancer+ FFPE Kit
CategoryNGS library preparation kit
Description

FFPE DNA kit (SEQ029) covering 15 genes plus MSI, pharmacogenetics (DPYD/UGT1A1), and therapy guidance markers including BRAF, KRAS, NRAS, TP53, EGFR, HER2, MET, designed for bowel cancer therapy guidance and Lynch syndrome testing.

11XCeloSeq Colon Cancer FFPE Kit
CategoryNGS library preparation kit
Description

FFPE DNA kit for detecting common colon cancer mutations across hotspots in 22 genes and 5 DPYD SNPs from FFPE-preserved samples.

12XCeloSeq Lung Cancer Fusion Kit
CategoryNGS library preparation kit
Description

Targeted RNA kit (SEQ008) for capturing gene fusions from 15 genes frequently involved in lung cancer chromosomal rearrangements from FFPE RNA samples.

13XCeloSeq Solid Cancer Fusion Kit
CategoryNGS library preparation kit
Description

Targeted RNA kit (SEQ012) for capturing gene fusions from 53 genes frequently involved in solid cancer chromosomal rearrangements from FFPE RNA samples.

14XCeloSeq Actionable Fusion Kit
CategoryNGS library preparation kit
Description

Targeted RNA kit (SEQ015) for capturing gene fusions from 12 genes involved in therapy guidance for targeted cancer treatments from FFPE RNA samples.

15XCeloSeq Lymphoma Fusion Kit
CategoryNGS library preparation kit
Description

Targeted RNA kit (SEQ018) for capturing gene fusions from 33 genes frequently involved in lymphoma chromosomal rearrangements from FFPE RNA samples.

16XCeloSeq Myeloid Fusion Kit
CategoryNGS library preparation kit
Description

Targeted RNA kit (SEQ017) for capturing gene fusions from 39 genes frequently involved in myeloid malignancy chromosomal rearrangements from FFPE RNA samples.

17XCeloSeq ALL Fusion Kit
CategoryNGS library preparation kit
Description

Targeted RNA kit (SEQ019) for capturing gene fusions from 44 genes frequently involved in acute lymphoblastic leukaemia chromosomal rearrangements from FFPE RNA samples.

18XCeloSeq Sarcoma Fusion Kit
CategoryNGS library preparation kit
Description

Targeted RNA kit (SEQ014) for capturing gene fusions from 26 genes frequently involved in sarcoma chromosomal rearrangements from FFPE RNA samples.

19XCeloSeq cfDNA Library Prep Kit
CategoryNGS library preparation kit
Description

Whole-sample library preparation kit (SEQ001) capturing all single- and double-strand DNA from cell-free DNA samples with 2.0 hours of hands-on time using ATOM-Seq technology.

20XCeloSeq Methyl-cfDNA Kit
CategoryNGS library preparation kit
Description

Methylation analysis workflow kit (SEQ004) that captures cell-free DNA and enriches high-GC DNA to support improved coverage of CpG islands for epigenetic analysis with 2.5 hours of hands-on time.

21JAK2 Mutation Detection Kit (V617F)
CategoryqPCR diagnostic kit
Description

Real-time PCR mutation detection kit using MMD technology that enables detection of the V617F mutation in the JAK2 gene against a background of wild-type genomic DNA for myeloproliferative disorder diagnostics.

22ABL Mutation Detection Kit (T315I)
CategoryqPCR diagnostic kit
Description

Real-time PCR mutation detection kit using MMD technology that enables detection of the T315I mutation in the ABL gene for managing CML patients resistant to tyrosine kinase inhibitors.

23XCeloSeq Custom Panels
CategoryCustom assay development service
Description

Custom assay development service for cfDNA, RNA, and FFPE workflows including applications for treatment response monitoring, minimal residual disease (MRD), organ rejection monitoring, CRISPR genome edit tracking, and viral integration mapping; manufacturing performed under ISO 13485 certification.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
1Aquarius Population Health
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-07-07
Description

Health economics consultancy partnership for developing economic evidence supporting adoption of GeneFirst's syndromic multiplexed PCR tests into clinical practice. Part of IHI-funded RAPID COVID consortium project.

genefirst.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-07-07
Description

Consortium project partners including Assistance Publique – Hôpitaux de Paris, Hospital Costa Del Sol, Biosistemika, and PrimaDiag for developing syndromic testing strategy for respiratory diseases.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-02-22
Description

Collaborative partnership for development of predictive diagnostic panel for HPV infections evolving into cervical cancer, funded by £1.4M NIHR grant awarded to GeneFirst and University of Leeds.

4Hiantis
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaboration as part of HPV OncoPredict project for developing diagnostic tests to identify women with HPV infection at higher risk of developing cervical cancer.

genefirst.com
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

US-based distributor for GeneFirst products

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Thailand-based distributor following Thai FDA approval of Papilloplex HR-HPV kits

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Austria and Germany-based distributor for GeneFirst products in Europe

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Chile-based distributor for GeneFirst products in Latin America

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Japan-based distributor for GeneFirst products

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Global leader in sample preparation and molecular diagnostics kits, including NGS library prep and HPV testing. Closely comparable to GeneFirst's ATOM-Seq-based XCeloSeq kits and Papilloplex HPV assays, serving the same clinical and research customers.

TypeDirect peer
Description

Provides NGS target enrichment and library preparation products, including custom panels for cfDNA and oncology. Directly comparable to GeneFirst's XCeloSeq targeted and custom NGS kits using ATOM-Seq technology.

TypeDirect peer
Description

Major supplier of NGS library prep, qPCR assays, and custom oligonucleotides used by the same molecular diagnostics customers as GeneFirst. Overlaps with XCeloSeq kits, MMD-PCR mutation detection, and custom panel services.

TypeDirect peer
Description

Markets the Aptima HPV assays (DNA and mRNA) for cervical cancer screening on the Panther platform. Directly competes with GeneFirst's Papilloplex HR-HPV DNA and mRNA kits in the high-risk HPV genotyping market.

TypeBroad incumbent
Description

Broad molecular diagnostics portfolio including cobas HPV tests, ctDNA liquid biopsy assays, and the AVENIO NGS kits. Overlaps with nearly all of GeneFirst's product verticals (HPV, oncology NGS, respiratory).

TypeBroad incumbent
Description

Through its Diagnostics and ProteinSimple segments, Bio-Techne offers molecular diagnostics reagents and exosome/EV-related workflows relevant to cfDNA/FFPE sample prep. Comparable as a tools-grade supplier to clinical and research labs.

TypeBroad incumbent
Description

Operates the GeneXpert system with a broad menu of CE-IVD/FDA-cleared molecular assays including respiratory pathogen panels and HPV. Overlaps with GeneFirst's multiplex PCR respiratory panels on the customer/clinical side.

TypeEmerging player
Description

Specializes in cfDNA-based liquid biopsy tests for oncology (Signatera) and reproductive health. Comparable to GeneFirst's XCeloSeq cfDNA liquid biopsy kits as an end-user and emerging competitor in ctDNA workflows.

TypeEmerging player
Description

Offers highly sensitive digital PCR and NGS services for ctDNA oncology testing (SafeSEQ, Plasma-Sequencing). Comparable to GeneFirst's ultra-sensitive mutation detection claims (0.1% MMD-PCR) in the oncology liquid biopsy niche.

10Respiratory pathogens panel developers (e.g., BioMérieux BioFire, QIAGEN QIAstat-Dx)
TypeBroad incumbent
Description

Syndromic multiplex respiratory panels (FilmArray, QIAstat-Dx) directly compete with GeneFirst's CE-IVD Upper and Lower Respiratory Panels for hospital-adopted pneumonia and viral testing.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration8 records

Each record includes

Title, Type, Description, Source

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

GeneFirst

Molecular Diagnosticsgenefirst.com

GeneFirst is a UK-based molecular diagnostics company that develops proprietary NGS (ATOM-Seq) and qPCR (MPA, MMD-PCR) kits for oncology, infectious disease, and personalised medicine, serving healthcare laboratories, researchers, and pharmaceutical companies through direct UK sales and a global distributor network.

What GeneFirst does

GeneFirst Limited is a privately-held molecular diagnostics company founded in 2011 and headquartered at Abingdon Science Park, Oxfordshire, UK. It develops and commercialises proprietary NGS library preparation and qPCR technologies for infectious disease, cancer diagnostics, and personalised medicine, serving healthcare laboratories, researchers, and pharmaceutical/drug companies. Its technology platform is anchored by ATOM-Seq (Adaptor Template Oligo Mediated Sequencing), a patented ligation-free NGS library preparation method that incorporates Unique Molecular Identifiers directly onto sample molecules, complemented by MPA (Multiplex Probe Amplification), MMD-PCR (Multiplex Mutation Detection PCR), and PCDR (Polymerase Chain Displacement Reaction) chemistries. The commercial product portfolio comprises the XCeloSeq NGS kit family (targeted cfDNA, FFPE DNA/RNA, fusion detection, methylation, and custom panels), the CE-IVD marked Papilloplex HR-HPV DNA and mRNA kits for cervical cancer screening, CE-IVD marked Upper and Lower Respiratory Panels, and qPCR mutation detection kits (JAK2 V617F, ABL T315I).

The company generates revenue primarily through one-time sales of its diagnostic kits and NGS reagents, supplemented by a technology licensing channel for MPA and MMD. Distribution is quote-based, executed through direct sales in the UK and a network of regional distributors covering 20+ countries across the Americas, Asia-Pacific, Europe, and the Middle East, with manufacturing under ISO:13485 certification. To date the company has been funded almost entirely through competitive non-dilutive grants — two Innovate UK awards (2017), a €2.9M Horizon 2020 grant (2018), and a £1.4M NIHR grant with the University of Leeds (2021) — rather than venture capital, and has no disclosed PE, VC, or parent company ownership. Recent strategic activity includes Thai FDA approval for the Papilloplex HR-HPV kits and the launch of second-generation XCeloSeq cfDNA kits, both in June 2026, alongside active academic and consortium partnerships in HPV, respiratory, and oncology applications.

GeneFirst firmographics

Firmographics
Name
GeneFirst
Legal name
GeneFirst Limited
Website
https://genefirst.com
Company type
Private
Founded year
2011
Operating status
Operating
Headcount range
1–10 employees
Short description
GeneFirst is a UK-based molecular diagnostics company that develops proprietary NGS (ATOM-Seq) and qPCR (MPA, MMD-PCR) kits for oncology, infectious disease, and personalised medicine, serving healthcare laboratories, researchers, and pharmaceutical companies through direct UK sales and a global distributor network.
Ownership category
akta.pro rank

GeneFirst industry classification

Industry
Product category
Molecular Diagnostics
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAHAAAD
Molecular Diagnostics (PCR/NAAT/NGS-based IVD)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAGAIAF
Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays)
SECONDARYHLAAALAL
Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays)

Keywords

  • Molecular diagnostics kits
  • NGS library preparation
  • Cancer mutation detection
  • HPV genotyping assays
  • Respiratory pathogen PCR

Where GeneFirst is headquartered

Location

Headquarters

HQ city
Abingdon
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

GeneFirst business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Technology or R&D, Personnel, Marketing or Sales, Operations

Revenue model

  1. NGS Library Preparation Kits: Sale of XCeloSeq product line including targeted cfDNA kits, FFPE DNA/RNA kits, fusion detection kits, and total cfDNA capture kits for next-generation sequencing applications.
  2. qPCR Diagnostic Kits: Sale of HPV screening assays (Papilloplex HR-HPV DNA and mRNA kits), respiratory infection panels (Upper and Lower Respiratory Panels), and mutation detection kits (JAK2, ABL).
  3. Technology Licensing: Licensing opportunities available for MPA and MMD technologies to other companies.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

GeneFirst product offering

Product offering

Core offering

GeneFirst develops and manufactures proprietary molecular diagnostic kits and reagents based on its patented ATOM-Seq NGS capture chemistry and MPA/MMD/PCDR qPCR technologies. The company's commercial product range spans CE-IVD marked HPV and respiratory infection assays, XCeloSeq NGS kits for liquid biopsy and FFPE tissue analysis across multiple cancer types, and qPCR mutation detection kits targeting oncology biomarkers. These products are sold to researchers, clinical laboratories, and pharmaceutical companies for cancer diagnostics, infectious disease detection, and personalised medicine applications.

Product overview

GeneFirst is a molecular diagnostics company offering a portfolio of proprietary NGS library preparation and qPCR technologies focused on oncology, infectious diseases, and personalised medicine. The core technology platform is ATOM-Seq (Adaptor Template Oligo Mediated Sequencing), a patented ligation-free NGS library preparation method that incorporates Unique Molecular Identifiers (UMIs) directly onto sample molecules, which underpins the XCeloSeq product line for targeted and whole-sample cfDNA/FFPE DNA/FFPE RNA analysis. The qPCR portfolio includes MPA (Multiplex Probe Amplification) technology enabling high-throughput multiplex detection and MMD-PCR (Multiplex Mutation Detection PCR) for cancer mutation detection. Product portfolio spans: (1) NGS kits including targeted cfDNA kits for liquid biopsy mutation detection (Colon, Lung, Breast Cancer, Pan Cancer), FFPE DNA/RNA kits for fusion detection across multiple cancer types, and total cfDNA capture kits including methylation analysis; (2) CE-IVD marked diagnostic kits including Papilloplex HR-HPV DNA and mRNA assays for cervical cancer screening, and Upper/Lower Respiratory Panels for infectious disease detection; (3) qPCR mutation detection kits for JAK2 and ABL markers. All products are supported by ISO:13485 certified manufacturing at the Oxfordshire facility.

Differentiator

Problem solved

Functional benefit

Products and services

  • Papilloplex HR-HPV DNA Kit (CE-IVD) CE-IVD marked qPCR assay based on MPA technology for simultaneous detection and differentiation of 14 high-risk HPV genotypes (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68) targeting the E6/E7 region with 100% clinical sensitivity, intended for cervical cancer screening laboratories.
  • Papilloplex HR-HPV mRNA Kit (CE-IVD) CE-IVD marked qPCR assay that detects E6/E7 mRNA expression from high-risk HPV genotypes to identify cervical cancer risk in HPV-positive individuals, complementing the Papilloplex HR-HPV DNA Kit.
  • Upper Respiratory Panel (CE-IVD) CE-IVD marked multiplex PCR test detecting 11 pathogens in upper respiratory tract specimens including Adenovirus, Bocavirus, HCoV strains, hPIV1-4, Influenza A/B, Metapneumovirus, Mycoplasma pneumoniae, RSV, Rhinovirus, and SARS-CoV-2 variants.
  • Lower Respiratory Panel (CE-IVD) CE-IVD marked multiplex PCR test detecting 9 pathogens associated with community-acquired pneumonia including Bordetella pertussis, Coxiella burnetii, Haemophilus influenzae, Legionella pneumophila, Moraxella catarrhalis, Pneumocystis jirovecii, Staphylococcus aureus, and Streptococcus pneumoniae.
  • XCeloSeq Colon Cancer cfDNA Kit V2 Targeted cfDNA enrichment kit using ATOM-Seq v2 capture chemistry to detect mutations across hotspot regions of 22 colon cancer genes and 5 DPYD pharmacogenetics SNPs from liquid biopsy samples (SEQ031).
  • XCeloSeq Lung Cancer cfDNA Kit V2 Targeted cfDNA enrichment kit using ATOM-Seq v2 capture chemistry to detect mutations across 17 genes frequently mutated in lung cancer from liquid biopsy samples (SEQ032).
  • XCeloSeq Breast Cancer cfDNA Kit V2 Targeted cfDNA enrichment kit using ATOM-Seq v2 capture chemistry to detect mutations across 12 genes frequently mutated in breast cancer from liquid biopsy samples (SEQ033).
  • XCeloSeq Pan Cancer cfDNA Kit V2 Targeted cfDNA enrichment kit using ATOM-Seq v2 capture chemistry for pan-cancer liquid biopsy mutation profiling across multiple tumour types.
  • XCeloSeq Fusion Research Kit NGS library preparation kit (SEQ007) using ATOM-Seq technology to capture and enrich gene fusions from 74 genes involved in chromosomal rearrangements in cancer, detecting both known and unknown fusion events from FFPE RNA samples.
  • XCeloSeq Precision Colon Cancer+ FFPE Kit FFPE DNA kit (SEQ029) covering 15 genes plus MSI, pharmacogenetics (DPYD/UGT1A1), and therapy guidance markers including BRAF, KRAS, NRAS, TP53, EGFR, HER2, MET, designed for bowel cancer therapy guidance and Lynch syndrome testing.
  • XCeloSeq Colon Cancer FFPE Kit FFPE DNA kit for detecting common colon cancer mutations across hotspots in 22 genes and 5 DPYD SNPs from FFPE-preserved samples.
  • XCeloSeq Lung Cancer Fusion Kit Targeted RNA kit (SEQ008) for capturing gene fusions from 15 genes frequently involved in lung cancer chromosomal rearrangements from FFPE RNA samples.
  • XCeloSeq Solid Cancer Fusion Kit Targeted RNA kit (SEQ012) for capturing gene fusions from 53 genes frequently involved in solid cancer chromosomal rearrangements from FFPE RNA samples.
  • XCeloSeq Actionable Fusion Kit Targeted RNA kit (SEQ015) for capturing gene fusions from 12 genes involved in therapy guidance for targeted cancer treatments from FFPE RNA samples.
  • XCeloSeq Lymphoma Fusion Kit Targeted RNA kit (SEQ018) for capturing gene fusions from 33 genes frequently involved in lymphoma chromosomal rearrangements from FFPE RNA samples.
  • XCeloSeq Myeloid Fusion Kit Targeted RNA kit (SEQ017) for capturing gene fusions from 39 genes frequently involved in myeloid malignancy chromosomal rearrangements from FFPE RNA samples.
  • XCeloSeq ALL Fusion Kit Targeted RNA kit (SEQ019) for capturing gene fusions from 44 genes frequently involved in acute lymphoblastic leukaemia chromosomal rearrangements from FFPE RNA samples.
  • XCeloSeq Sarcoma Fusion Kit Targeted RNA kit (SEQ014) for capturing gene fusions from 26 genes frequently involved in sarcoma chromosomal rearrangements from FFPE RNA samples.
  • XCeloSeq cfDNA Library Prep Kit Whole-sample library preparation kit (SEQ001) capturing all single- and double-strand DNA from cell-free DNA samples with 2.0 hours of hands-on time using ATOM-Seq technology.
  • XCeloSeq Methyl-cfDNA Kit Methylation analysis workflow kit (SEQ004) that captures cell-free DNA and enriches high-GC DNA to support improved coverage of CpG islands for epigenetic analysis with 2.5 hours of hands-on time.
  • JAK2 Mutation Detection Kit (V617F) Real-time PCR mutation detection kit using MMD technology that enables detection of the V617F mutation in the JAK2 gene against a background of wild-type genomic DNA for myeloproliferative disorder diagnostics.
  • ABL Mutation Detection Kit (T315I) Real-time PCR mutation detection kit using MMD technology that enables detection of the T315I mutation in the ABL gene for managing CML patients resistant to tyrosine kinase inhibitors.
  • XCeloSeq Custom Panels Custom assay development service for cfDNA, RNA, and FFPE workflows including applications for treatment response monitoring, minimal residual disease (MRD), organ rejection monitoring, CRISPR genome edit tracking, and viral integration mapping; manufacturing performed under ISO 13485 certification.

Quantifiable outcome

  • ATOM-Seq captures up to 179% more cfDNA molecules compared to ligation-based capture chemistry
  • +3 more outcomes

Companies that use GeneFirst

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles2 records

GeneFirst technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration8 records

AI capability3 records

Feature4 records

GeneFirst partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered minor and core.

  • Aquarius Population HealthminorStrategic or Co-development Partner · 7 July 2023Health economics consultancy partnership for developing economic evidence supporting adoption of GeneFirst's syndromic multiplexed PCR tests into clinical practice. Part of IHI-funded RAPID COVID consortium project.
  • Innovative Health Initiative (IHI) Consortium - RAPID COVIDminorStrategic or Co-development Partner · 7 July 2023Consortium project partners including Assistance Publique – Hôpitaux de Paris, Hospital Costa Del Sol, Biosistemika, and PrimaDiag for developing syndromic testing strategy for respiratory diseases.
  • University of LeedscoreStrategic or Co-development Partner · 22 February 2021Collaborative partnership for development of predictive diagnostic panel for HPV infections evolving into cervical cancer, funded by £1.4M NIHR grant awarded to GeneFirst and University of Leeds.
  • HiantisminorStrategic or Co-development PartnerCollaboration as part of HPV OncoPredict project for developing diagnostic tests to identify women with HPV infection at higher risk of developing cervical cancer.
  • Calibre ScientificminorChannel Partner/ Reseller/ DistributorUS-based distributor for GeneFirst products
  • WinnergyminorChannel Partner/ Reseller/ DistributorThailand-based distributor following Thai FDA approval of Papilloplex HR-HPV kits
  • HiSS Diagnostics GmbhminorChannel Partner/ Reseller/ DistributorAustria and Germany-based distributor for GeneFirst products in Europe
  • BiocantminorChannel Partner/ Reseller/ DistributorChile-based distributor for GeneFirst products in Latin America
  • FilgenminorChannel Partner/ Reseller/ DistributorJapan-based distributor for GeneFirst products

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

GeneFirst competitors and assessment

Company assessment

Direct peers

  • Qiagen: Global leader in sample preparation and molecular diagnostics kits, including NGS library prep and HPV testing. Closely comparable to GeneFirst's ATOM-Seq-based XCeloSeq kits and Papilloplex HPV assays, serving the same clinical and research customers.
  • Twist Bioscience: Provides NGS target enrichment and library preparation products, including custom panels for cfDNA and oncology. Directly comparable to GeneFirst's XCeloSeq targeted and custom NGS kits using ATOM-Seq technology.
  • Integrated DNA Technologies (IDT, part of Danaher): Major supplier of NGS library prep, qPCR assays, and custom oligonucleotides used by the same molecular diagnostics customers as GeneFirst. Overlaps with XCeloSeq kits, MMD-PCR mutation detection, and custom panel services.
  • Hologic: Markets the Aptima HPV assays (DNA and mRNA) for cervical cancer screening on the Panther platform. Directly competes with GeneFirst's Papilloplex HR-HPV DNA and mRNA kits in the high-risk HPV genotyping market.

Broad incumbents

  • Roche Diagnostics: Broad molecular diagnostics portfolio including cobas HPV tests, ctDNA liquid biopsy assays, and the AVENIO NGS kits. Overlaps with nearly all of GeneFirst's product verticals (HPV, oncology NGS, respiratory).
  • Bio-Techne: Through its Diagnostics and ProteinSimple segments, Bio-Techne offers molecular diagnostics reagents and exosome/EV-related workflows relevant to cfDNA/FFPE sample prep. Comparable as a tools-grade supplier to clinical and research labs.
  • Cepheid (Danaher): Operates the GeneXpert system with a broad menu of CE-IVD/FDA-cleared molecular assays including respiratory pathogen panels and HPV. Overlaps with GeneFirst's multiplex PCR respiratory panels on the customer/clinical side.
  • Respiratory pathogens panel developers (e.g., BioMérieux BioFire, QIAGEN QIAstat-Dx): Syndromic multiplex respiratory panels (FilmArray, QIAstat-Dx) directly compete with GeneFirst's CE-IVD Upper and Lower Respiratory Panels for hospital-adopted pneumonia and viral testing.

Emerging players

  • Natera: Specializes in cfDNA-based liquid biopsy tests for oncology (Signatera) and reproductive health. Comparable to GeneFirst's XCeloSeq cfDNA liquid biopsy kits as an end-user and emerging competitor in ctDNA workflows.
  • Sysmex Inostics: Offers highly sensitive digital PCR and NGS services for ctDNA oncology testing (SafeSEQ, Plasma-Sequencing). Comparable to GeneFirst's ultra-sensitive mutation detection claims (0.1% MMD-PCR) in the oncology liquid biopsy niche.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

GeneFirst social profiles

Digital presence

GeneFirst compliance and trust

Trust signal

Compliance3 records

GeneFirst financial estimates

Financial estimate

Revenue estimate

Valuation estimate

GeneFirst leadership team

Management profile

Number of profiles

Profiles5 records

GeneFirst funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

GeneFirst M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GeneFirst

What does GeneFirst do?

GeneFirst develops and manufactures proprietary molecular diagnostic kits and reagents based on its patented ATOM-Seq NGS capture chemistry and MPA/MMD/PCDR qPCR technologies. The company's commercial product range spans CE-IVD marked HPV and respiratory infection assays, XCeloSeq NGS kits for liquid biopsy and FFPE tissue analysis across multiple cancer types, and qPCR mutation detection kits targeting oncology biomarkers. These products are sold to researchers, clinical laboratories, and pharmaceutical companies for cancer diagnostics, infectious disease detection, and personalised medicine applications.

Is GeneFirst a public or private company?

GeneFirst is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was GeneFirst founded?

GeneFirst was founded in 2011. It employs 1 to 10 people.

Where is GeneFirst based?

GeneFirst is headquartered in Abingdon, United Kingdom, in the Europe region.

How does GeneFirst make money?

Three revenue lines are on record. NGS Library Preparation Kits are the primary driver. The others are qPCR Diagnostic Kits and technology Licensing.

Who are GeneFirst's main competitors?

Direct peers on record are Qiagen, Twist Bioscience, Integrated DNA Technologies (IDT, part of Danaher) and Hologic. Broad incumbents are Roche Diagnostics, Bio-Techne, Cepheid (Danaher) and Respiratory pathogens panel developers (e.g., BioMérieux BioFire, QIAGEN QIAstat-Dx). Emerging players are Natera and Sysmex Inostics.

Does GeneFirst have an API?

No public API is recorded for GeneFirst.

What industry is GeneFirst in?

GeneFirst's product category is Molecular Diagnostics. Its primary akta.pro industry code is HLAHAAAD, Molecular Diagnostics (PCR/NAAT/NGS-based IVD), with a secondary code of HLAGAIAF, Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals